Related Experiment Video
Updated: Jul 4, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
"Triple-Punch" Strategy Exosome-Mimetic Nanovesicles for Triple Negative Breast Cancer Therapy
Chenhong Zhang1, Shuangshuang Tang1, Meilin Wang1
1School of Medicine, State Key Laboratory of Medicinal Chemical Biology, Nankai University, 94 Weijin Road, Tianjin 300071, China.
Abstract:
Triple-negative breast cancer (TNBC) is the most malignant breast cancer, with high rates of relapse and metastasis. Because of the nonspecific targeting of chemotherapy and insurmountable aggressiveness, TNBC therapy lacks an effective strategy. Exosomes have been reported as an efficient drug delivery system (DDS). CD82 is a tumor metastasis inhibitory molecule that is enriched in exosomes. Aptamer AS1411 specifically targets TNBC cells due to its high expression of nucleolin. We generated a "triple-punch" cell membrane-derived exosome-mimetic nanovesicle system that integrated with CD82 overexpression, AS1411 conjugation, and doxorubicin (DOX) delivery. CD82 enrichment effectively inhibits the migration of TNBC cells. AS1411 conjugation specifically targets TNBC cells. DOX loading effectively inhibits proliferation and induces apoptosis of TNBC cells. Our results demonstrate a system of exosome-mimetic nanovesicles with "triple-punch" that may facilitate TNBC therapeutics.
Insights
This study presents a novel nanovesicle system for triple-negative breast cancer (TNBC) therapy. It combines CD82, AS1411 aptamer, and doxorubicin (DOX) to target and treat aggressive TNBC tumors.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Triple-negative breast cancer (TNBC) is highly aggressive with poor therapeutic outcomes.
- Current chemotherapy lacks specificity and effectiveness against TNBC.
- Exosomes show promise as drug delivery systems (DDS).
Purpose of the Study:
- To develop an exosome-mimetic nanovesicle system for targeted TNBC therapy.
- To integrate CD82, AS1411 aptamer, and doxorubicin (DOX) for a multi-pronged therapeutic approach.
Main Methods:
- Engineered cell membrane-derived nanovesicles.
- Overexpressed CD82 for metastasis inhibition.
- Conjugated AS1411 aptamer for specific TNBC cell targeting.
- Loaded nanovesicles with doxorubicin (DOX) for cell killing.
Main Results:
- CD82 enrichment significantly inhibited TNBC cell migration.
- AS1411 conjugation achieved specific targeting of TNBC cells.
- DOX loading effectively suppressed proliferation and induced apoptosis in TNBC cells.
Conclusions:
- The developed "triple-punch" exosome-mimetic nanovesicle system shows potential for effective TNBC treatment.
- This integrated approach offers a promising strategy to overcome TNBC aggressiveness and improve therapeutic efficacy.
